The Lausanne, Switzerland-based company develops technology for near-real-time continuous biochemical monitoring. It said the new funding enables the acceleration of the development and clinical validation of its Lab-on-Skin wearable biosensing platform.
Xsensio designed Lab-on-Skin to provide dynamic, multi-modal, biochemical information. It aims to support clinical decision-making in the hospital and beyond.
The platform offers real-time, continuous tracking of inflammation and other critical biomarkers. Xensio wants to enable earlier detection of clinical deterioration in a variety of settings, including ICUs, outpatient care and the home. The company’s first product focuses on the early detection of organ dysfunction.
Venture capital firm WI Harper led the Series A round. Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe and Asia, also participated
“This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments,” said Esmeralda Megally, CEO of Xsensio. “For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care. This capability has the potential to fundamentally improve how patients are monitored and treated.”
In parallel, the company announced a long-term collaboration with semiconductor technology leader Texas Instruments. It hopes to enable CMOS integration, miniaturization and large-scale manufacturability of biosensing systems to strengthen industrial scalability.
“Our collaboration with Texas Instruments significantly strengthens our path to advanced, scalable semiconductor technology,” added Adrian Ionescu, CTO of Xsensio. “By combining our biosensing innovation with world-class semiconductor expertise, we are building a platform designed not only for clinical impact, but also for reliable, cost-effective deployment.”
